| 1 | aquashine br soft filler | | | | | | | 5 | 0.41% |
| 2 | revofil aquashine br soft | | | | | | | 5 | 0.41% |
| 3 | e p t qeptq | | | | | | | 4 | 0.33% |
| 4 | durable and natural looking | | | | | | | 3 | 0.25% |
| 5 | gradually absorbed into the | | | | | | | 3 | 0.25% |
| 6 | are human by selecting | | | | | | | 3 | 0.25% |
| 7 | human by selecting the | | | | | | | 3 | 0.25% |
| 8 | please prove you are | | | | | | | 3 | 0.25% |
| 9 | is botu linum type | | | | | | | 3 | 0.25% |
| 10 | botu linum type a | | | | | | | 3 | 0.25% |
| 11 | and natural looking of | | | | | | | 3 | 0.25% |
| 12 | beauty co limited is | | | | | | | 3 | 0.25% |
| 13 | you are human by | | | | | | | 3 | 0.25% |
| 14 | audrey beauty co limited | | | | | | | 3 | 0.25% |
| 15 | effective product is an | | | | | | | 3 | 0.25% |
| 16 | absorbed into the skin | | | | | | | 3 | 0.25% |
| 17 | prove you are human | | | | | | | 3 | 0.25% |
| 18 | looking of all course | | | | | | | 3 | 0.25% |
| 19 | solid durable and natural | | | | | | | 3 | 0.25% |
| 20 | all course of time | | | | | | | 3 | 0.25% |
| 21 | natural looking of all | | | | | | | 3 | 0.25% |
| 22 | the treatmentnaturally volume and | | | | | | | 3 | 0.25% |
| 23 | of time when it | | | | | | | 3 | 0.25% |
| 24 | course of time when | | | | | | | 3 | 0.25% |
| 25 | treatmentnaturally volume and lookmuch | | | | | | | 3 | 0.25% |
| 26 | of all course of | | | | | | | 3 | 0.25% |
| 27 | throughout the treatmentnaturally volume | | | | | | | 3 | 0.25% |
| 28 | is a safe stable | | | | | | | 2 | 0.17% |
| 29 | designed for subcutaneous injection | | | | | | | 2 | 0.17% |
| 30 | filler designed for subcutaneous | | | | | | | 2 | 0.17% |
| 31 | acid filler designed for | | | | | | | 2 | 0.17% |
| 32 | hyaluronic acid filler designed | | | | | | | 2 | 0.17% |
| 33 | hyaluronate ha dermal filler | | | | | | | 2 | 0.17% |
| 34 | linum type a developed | | | | | | | 2 | 0.17% |
| 35 | tox is botu linum | | | | | | | 2 | 0.17% |
| 36 | an excellent solution for | | | | | | | 2 | 0.17% |
| 37 | type a developed by | | | | | | | 2 | 0.17% |
| 38 | for antiaging and skin | | | | | | | 2 | 0.17% |
| 39 | products for antiaging and | | | | | | | 2 | 0.17% |
| 40 | aesthetic products for antiaging | | | | | | | 2 | 0.17% |